A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD

BACKGROUND: Long-acting muscarinic antagonist (LAMA) and long-acting β(2)-agonist (LABA) bronchodilators are key to the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). This Phase IIb study investigated the safety and efficacy of four doses of the LAMA glycopyrronium (GP) del...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Kerwin, Edward M., Spangenthal, Selwyn, Kollar, Christine, St Rose, Earl, Reisner, Colin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838878/
https://ncbi.nlm.nih.gov/pubmed/29506504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0739-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados